Please use this identifier to cite or link to this item:
|Title:||Postoperative pulmonary complications in the ENIGMA II Trial: A post hoc analysis.||Austin Authors:||Peyton, Philip J ;Liskaser, Grace;Ho, Alexander;Marsh, Harry ;Etherington, Christopher;Torlot, Freddie;Desai, Manisha;Perrett, George;Chee, Brian;Leslie, Kate;Myles, Paul S||Affiliation:||Austin Health
Barwon Health, Geelong, Victoria, Australia.
Royal Perth Hospital, Perth, Western Australia.
Fremantle Hospital, Fremantle, Western Australia.
Westmead Hospital, Sydney, New South Wales, Australia.
Dept of Critical Care, Melbourne Medical School, University of Melbourne, Victoria, Australia.
The Alfred, Melbourne, Victoria, Australia.
|Issue Date:||16-Jan-2023||metadata.dc.date:||2023||Publication information:||Anesthesiology 2023||Abstract:||Nitrous oxide (N2O) promotes absorption atelectasis in poorly ventilated lung segments at high inspired concentrations. The ENIGMA Trial found a higher incidence of postoperative pulmonary complications (PPCs) and wound sepsis with N2O anesthesia in major surgery compared to FIO2 0.8 without N2O. The larger ENIGMA II trial randomised patients to N2O or air at FIO2 0.3 but found no effect on wound infection or sepsis. However, postoperative pulmonary complications were not measured. In the current study we collected post hoc data to determine if atelectasis and pneumonia incidences were higher with N2O in patients who were recruited to the Australian cohort of ENIGMA II.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/32024||DOI:||10.1097/ALN.0000000000004497||ORCID:||0000-0003-1185-2869
||Journal:||Anesthesiology||PubMed URL:||36645804||ISSN:||1528-1175||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Jan 31, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.